Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow References
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Jackson, G.
Right arrow Articles by Giuliano, F.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Jackson, G.
Right arrow Articles by Giuliano, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Moderators' introduction

G. Jackson1,1 and F. Giuliano2

a Cardiac Department, Guy's and St. Thomas' Hospital, London, U.K.
b Department of Urology, Centre Hospitalier Universitaire de Bicêtre, AP-HP, Le Kremlin-Bicêtre, France

1 Correspondence: Graham Jackson, MD, Cardiac Department, St. Thomas' Hospital, Lambeth Palace Road, London SE1 7EH, U.K..

Abstract

Sexuality is an integral component of male health and well being, and both the diagnosis and treatment of erectile dysfunction represent clear medical priorities. The close epidemiological, pathophysiological and clinical links between erectile dysfunction (or insufficiency) and cardiovascular disease warrant consideration by cardiologists. Not only do these conditions share common risk factors, but erectile insufficiency may also be a risk marker for occult coronary heart disease or diabetes. Impaired endothelial-dependent smooth muscle relaxation is a potential mechanism for both erectile dysfunction and certain forms of cardiovascular disease. Phosphodiesterase type 5 inhibitors potentiate the erectile response to sexual stimulation by amplifying the nitric oxide signalling pathway. The present supplement offers an appraisal of the cardiovascular safety of sexual activity and treatment of erectile insufficiency with phosphodiesterase type 5 inhibitors; it explores potential uses of these agents in cardiovascular disease management; and it reviews the cardiovascular safety, tolerability and efficacy profiles of tadalafil — a novel phosphodiesterase type 5 inhibitor.

Key Words: Cardiovascular disease • diagnosis • erectile dysfunction • phosphodiesterase type 5 inhibitors • treatment


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.